Asia Spotlight: Ranbaxy CEO Arun Sawhney On “Thrilling” Days Of Atorvastatin Approvals And What’s Next
Executive Summary
Atorvastatin launch “reinforced the belief in the Indian generic companies,” Sawhney says. Approval of anti-malarial Synriam, the first novel drug developed in India, will lead to “belief that we from India can also develop new products.”